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Dermatomyositis (DM) is a chronic sys-
temic disease that primarily affects skin and/
or muscles and is associated with cancer in
about 20% of cases. Although DM is an auto-
immune disorder, there is evidence that
innate immunity plays a crucial role in the
disease. In particular, it has been associated
with elevated interferon (IFN)-β in blood1
which is critical in the initiation2 and per-
petuation3 of the disease. However, the
origin of elevated IFN-β remains elusive. It
has been speculated that it may result from
the engagement of endosomal toll-like recep-
tor (TLR) signalling due to the increased
expressions of TLR7 and TLR9 in peripheral
blood leucocytes4 of patients with DM, but
direct evidence of endosomal TLR involve-
ment in DM is lacking.
We report herein a patient who developed
severe exacerbation of anti-NXP2-positive
DM on imiquimod therapy, a potent TLR7
agonist approved for the treatment of cuta-
neous basocellular carcinoma. Peripheral
blood mononuclear cells (PBMC) analysis
revealed an increase in IFN-β secretion on
TLR7 stimulation, whereas TLR4-induced
pro-inﬂammatory cytokines secretion did not
differ from healthy matched controls. This
report not only provides evidence that endo-
somal TLR7 participates in human DM but
also pointed to the skin as a primary organ
allowing TLR7 agonists to induce DM ﬂare.
A woman aged 47 years presented with fever,
arthralgia, myalgia and a facial DM rash
(ﬁgure 1). She declared that a slight facial
rash suggesting of DM had been present for
over 1 year and that its exacerbation and extra-
cutaneous signs onset appeared 1 month after
starting topic imiquimod (5%, once daily) for
a cutaneous basocellular carcinoma of the
anterior chest wall (diagnosed 6 months after
DM rash onset). Temperature was 38°C, and
limb girdle muscles were painful but with no
signs of weakness. Joints of the hand were
tender without arthritis. C reactive protein
level was 1.5 mg/dL (normal <0.4) while creat-
ine kinase level was normal. She tested positive
Figure 1 Eyelid erythema and oedema after
imiquimod intake.
Key messages
What is already known about this subject?
▸ It has been speculated that elevated interferon
(IFN)-β in blood characterising dermatomyositis
patients results from the engagement of endoso-
mal toll-like receptor (TLR) signalling due to the
increased expressions of TLR7 and TLR9 in per-
ipheral blood leucocytes.
What does this study add?
▸ We provide direct evidence that supports this
hypothesis by reporting herein a patient who
developed severe exacerbation of anti-NXP2-
positive dermatomyositis (DM) on imiquimod
therapy, a potent TLR7 agonist and whose per-
ipheral blood mononuclear cells secreted high
level of IFN-β upon TLR7 stimulation as com-
pared with healthy donors.
How might this impact on clinical practice?
▸ These data indicate that aberrant TLR7 signalling
may represent a therapeutic target in DM.
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for anti-NXP2 antibodies (DTek and Euroimmun) and
negative for anti-Mi2, anti-SAE, anti-TIF1γ and anti-MDA5.
Electromyographic recordings were normal. Hand radio-
graphs demonstrated no damage. CT and spirometry
demonstrated no evidence of interstitial lung disease.
Cutaneous basocellular carcinoma had hardly disappeared
when she was diagnosed with DM and no other cancer was
found on 18F-FDG PET/CT, gastroscopy and colonoscopy.
Eyelids skin rash, polyarthralgia, fever and anti-NXP2
demonstrated by two immunoassay test kits indicate that
our patient did suffer from amyopathic DM. Accordingly,
she was successfully treated with prednisone, topical tacro-
limus for the DM rash and imiquimod discontinuation
(after 6 weeks treatment and complete clinical regression
of the basocellular carcinoma).
In vitro, TLR7 stimulation of the patient’s PBMC
(sampled 12 months after imiquimod discontinuation)
led to an increase in several pro-inﬂammatory cytokines
involved in DM,5 including IFN-β. Imiquimod also lead
to an increase in TLR7 expression in the PBMC of our
Figure 2 IFN-β, IL-6, TNF-α and CCL2 release were determined by ELISA in culture supernatants of PBMC stimulated with
LPS from Salmonella abortusequi (1 µg/mL Sigma–Aldrich (Saint-Quentin-Fallavier, France)) or imiquimod (5 µg/mL, Sigma–
Aldrich (Saint-Quentin-Fallavier, France)) for 3 hours. TLR7 expression was determined by RT-qPCR. Results were normalised to
Gapdh and expressed as fold change compared with samples from cells incubated in medium alone. PBMC was isolated from
the DM patient and three age-matched healthy controls. The patient had discontinued imiquimod 1-year topical tacrolimus
2 weeks before PBMC were sampled. CCL2, chemokine ligand 2; DM, dermatomyositis; IL-6, interleukin-6; INF-β, interferon-β;
LPS, lipopolysaccharide; PBMC, peripheral blood mononuclear cells; TLR7, toll-like receptor-7; TNF-α, tumour necrosis factor-α.
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patient but not in controls. Pro-inﬂammatory cytokine
secretion on TLR4 stimulation, which expression has
been reported to be unchanged in DM PBMC,4 did not
differ from age-matched female controls (ﬁgure 2).
The present report suggests that aberrant endosomal
TLR signalling, including high IFN-β secretion by PBMC
and TLR7 signal auto-ampliﬁcation, participates in DM.
Given the presence of a feed-forward loop between
IFN-β and TLR7 signalling,6 the latter is likely to partici-
pate in disease initiation and maintenance. This extends
the previous description of abnormal endosomal TLR
expression in PBMC of patients with DM.4 Natural
ligands of TLR7 in DM patients probably include micro-
bial RNA since a clinical history consistent with an infec-
tion is frequently reported prior to disease onset,7 but
endogenous RNAs are also likely to be involved notably
during cancer and UV radiation damages, two frequent
local conditions involving TLR7-mediated response8 9
and triggering DM. Consistently with this view, skin
TLR7 activation in mice10 and human11 has been previ-
ously reported to trigger lupus, an autoimmune disease
that is also characterised by a type on interferon signa-
ture in blood. These data indicate that TLR7 may repre-
sent a therapeutic target in DM.
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